Previous 10 | Next 10 |
Arena Pharmaceuticals, Inc. (ARNA) Q3 2020 Earnings Conference Call November 9, 2020 4:30 PM ET Company Participants Pat Malloy – Vice President, Investor Relations and Corporate Communications Amit Munshi – President and Chief Executive Officer Chris Cabell – Chief Medic...
Image source: The Motley Fool. Arena Pharmaceuticals Inc (NASDAQ: ARNA) Q3 2020 Earnings Call Nov 9, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: Arena Pharmaceuticals Inc (ARNA) Q3 2020 Earnings Call Transcript ...
Arena Pharmaceuticals (ARNA) slumps 20% after hours in reaction to results from a Phase 2b clinical trial, ADVISE, evaluating etrasimod (APD334) in patients with moderate-to-severe atopic dermatitis ((AD)).The study failed to achieve the primary endpoint of percent change in Eczema ...
Arena Reports Third Quarter Financial Results with Strong Cash Position, Advancing Etrasimod Into a Phase 3 Registrational Program in Atopic Dermatitis - Delivered compelling topline results from ADVISE Ph 2b trial evaluating etrasimod in atopic dermatitis; advancing into a Ph 3...
Arena Pharmaceuticals Advancing Etrasimod Into Phase 3 Program in Atopic Dermatitis (AD), Reports Compelling Topline Results from Phase 2b ADVISE Trial - Etrasimod 2 mg in the primary analysis achieved statistical significance of the registrational endpoint vIGA at week 12 -...
[[AL]], [[AMBC]], [[ARNA]], [[BYND]], [[CNXN]], [[DHT]], [[DIOD]], [[ELY]], [[GSKY]], [[HAIN]], [[IFF]], [[IHRT]], [[INO]], [[IPAR]], [[MBI]], [[MWA]], [[MYGN]], [[NBIX]], [[NCLH]], [[NGL]], [[NHI]], [[NKLA]], [[NVAX]], [[OR]], [[OSH]], [[OXY]], [[RAMP]], [[REAL]], [[RNG]], [[RPAY]], [[SCOR]]...
Arena Pharmaceuticals (NASDAQ:ARNA) is scheduled to announce Q3 earnings results on Monday, November 9th, after market close.The consensus EPS Estimate is -$1.86 (-27.4% Y/Y) and the consensus Revenue Estimate is $1.43M (+5.9% Y/Y).Analyst expects FY20 capital expenditure estimate $1.90M.Over...
Arena Pharmaceuticals to Release Third Quarter 2020 Financial Results and Provide Corporate Update on November 9 PR Newswire SAN DIEGO, Nov. 2, 2020 SAN DIEGO , Nov. 2, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its third...
Arena Pharmaceuticals (ARNA) and Longboard Pharmaceuticals launched launch of Longboard and completion of a $56M financing led by Farallon Capital Management and other top tier healthcare investors.Earlier, Longboard was a wholly-owned subsidiary of Arena and formerly known as Arena Neuroscie...
Arena Pharmaceuticals Announces Launch of Longboard Pharmaceuticals With $56M Financing, Building a Novel Neuroscience Drug Development Company - Longboard Pharmaceuticals (formerly Arena Neuroscience) is an Arena-founded independent company focused on advancing promising invest...
News, Short Squeeze, Breakout and More Instantly...
Arena Pharmaceuticals Inc. Company Name:
ARNA Stock Symbol:
NASDAQ Market:
Arena Pharmaceuticals Inc. Website:
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded at a new 52-week high today of $99.95. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.2 million shares. Arena Pharmaceuticals is a biotechnology company targeting G-protein-couple...
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded today at a new 52-week high of $98.57. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.1 million shares. Over the past year, Arena Pharmaceuticals Inc. has traded in a range of $45...